NEWS RELEASE

WEX Expands GLP-1 HRA Solution With Virtual Access Options, Member Support and Outcomes Management

2026-11-19

New offering with Patiently™ and Signos combines employer-controlled HRA funding, clinically guided GLP-1 access, and AI-powered lifestyle coaching – all in a single, flexible benefits solution

PORTLAND, Maine--(BUSINESS WIRE)-- WEX (NYSE: WEX), a global leader in intelligent payment solutions, today announced the expansion of its GLP-1 Health Reimbursement Arrangement (HRA) with two new strategic integrations: Patiently™ by FSA & HSA Store® and Signos. Through Patiently, employers will gain access to customizable and compliant GLP-1 treatment plans backed by ongoing clinical support, while Signos will provide GLP-1 access through verified telehealth screening paired alongside real-time metabolic monitoring, behavior-change coaching, and outcomes reporting. Together, these integrations will allow employers greater flexibility to manage costs, while providing employees with convenient access to personalized care.

Originally introduced in March 2026 to address skyrocketing prescription costs, the WEX GLP-1 HRA provides the foundational account infrastructure that helps make GLP-1 coverage more financially viable for employers and accessible for employees. Within that framework, employees will now be able to seamlessly deploy allocated benefit dollars to access GLP-1 coverage through either Patiently or Signos.

“Employees shouldn’t have to drain their savings or navigate a maze of branded portals just to access transformative care like GLP-1s,” said Robert Deshaies, Chief Operating Officer, Benefits at WEX. “At the same time, handing someone a high-cost prescription without guidance makes long-term success far harder to achieve and sustain. By pairing predictable HRA funding with telehealth support and real-time metabolic coaching, WEX and our

providers are removing anxiety and friction for workers, and instead providing them with the confidence and reliable access they need to help build lasting health – all while giving employers sustainable costs."

How It Works: A Modular, Three-Layer Solution

GLP-1 medications account for **approximately 20% of enterprise pharmacy spend**, with list prices averaging $900 to $1,500 monthly. Yet cost is only part of the hurdle. According to the **Employee Benefit Research Institute (EBRI)**, about 35% of GLP-1 users discontinued therapy early in 2025. Compounding the challenge, employers often receive utilization and claims data months after the fact, leaving benefits leaders unable to intervene early, course-correct, or evaluate return on investment.

To bridge this gap between medication access and sustainable outcomes, WEX structured its expanded GLP-1 HRA offering as a unified, modular framework. Employers can deploy the complete end-to-end model or integrate specific components into existing health plans:

- Employer-Controlled HRA Funding (WEX): Employers replace open-ended pharmacy benefits with a defined monthly or quarterly allowance. Organizations maintain full governance over eligibility, contribution caps, and reimbursement rules – allowing for more predictable budgeting without cutting off employee access.
- Guidance and Treatment Access (Patiently): With Patiently, Health-E Commerce's owned telehealth platform that is part of the WEX ecosystem, employees can explore a comprehensive range of GLP-1 treatments, including compounded and brand-name options, and access expert virtual care by connecting with a licensed provider from the comfort of their home. Upon approval, employees receive treatment directly at their door, without the need for in-person doctor's office visits or trips to the pharmacy. Ongoing clinical support encourages successful weight-loss outcomes, with helpful tips, side effect management, and dosage adjustments included for every patient.
- Continuous Metabolic Support and Real-Time Visibility (Signos): Employees can use their HRA funds to access GLP-1 therapy through Signos' own telehealth, paired with Signos' FDA-cleared, AI-powered continuous glucose monitoring system and coaching platform. Members see in real time how their food and activity choices affect their glucose and weight while on the medication, with embedded behavioral coaching and nutrition guidance that help them stay engaged and build habits that last – addressing the market's high treatment drop-off rates and inability to titrate off the drug.

The expanded, modular WEX GLP-1 HRA offering is available now for employers, partners, brokers, and consultants looking to modernize their weight-management benefit strategy and measure its impact in real time. To learn more about how WEX is helping organizations overcome the complexity of specialty drug coverage, visit **here**.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, statements regarding the expected benefits resulting from the Company's expansion of its GLP-1 HRA solution and integration of two new third party providers. Any statements in this press release that are not statements of historical facts are forward-looking statements. When used in this press release, the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "will," "positions," "confidence," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such words. Forward-looking statements relate to our future plans, objectives, expectations, and intentions and are not historical facts and accordingly involve known and unknown risks and uncertainties and other factors that may cause the actual results or performance to be materially different from future results or performance expressed or implied by these forward-looking statements, including the ability of the Company and its customers to realize the expected benefits of the Company's expansion of its GLP-1 HRA solution and integration of two new third party providers as well as other risks and uncertainties identified in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 13, 2026, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on October 29, 2026 and subsequent filings with the Securities and Exchange Commission. The forward-looking statements speak only as of the date of this press release and undue reliance should not be placed on these statements. The Company disclaims any obligation to update any forward-looking statements as a result of new information, future events, or otherwise.

About WEX

WEX (NYSE: WEX) is the global commerce platform that simplifies the business of running a business. WEX has created a powerful ecosystem that offers seamlessly embedded, personalized solutions for its customers around the world. Through its rich data and specialized expertise in simplifying benefits, reimagining mobility and paying and getting paid, WEX aims to make it easy for companies to overcome complexity and reach their full potential. For more information, please visit **www.wexinc.com.**

About Health-E Commerce®

Health-E Commerce® is the owner of the brands FSA Store® and HSA Store®, online stores that simplify pre-tax health spending for more than 70 million consumers enrolled in these accounts. Behind 100% guaranteed eligible products, vetted telehealth services, and the company's own Caring Mill® line of everyday health essentials at value pricing, these stores offer guesswork-free shopping, plus the tools and education account holders need to make the most of their funds. In 2026, the company introduced Patiently™, its fully owned virtual care experience, helping FSA and HSA participants get access to personalized prescription treatment by licensed providers. Beyond its consumer-facing brands, Health-E Commerce® works across the pre-tax health benefits landscape, maintaining a

regularly updated Eligibility List®, building partnerships with third-party administrators, and advancing consumer advocacy.

About Signos, Inc.

Launched in 2018, Signos, Inc. is on a mission to eliminate obesity by igniting the metabolic health movement. Powered by a continuous glucose monitor (CGM), the company's mobile AI-driven system offers personalized insights into how food, movement, sleep, stress, and more affect each unique body. Signos is the only FDA-cleared CGM system for weight management and requires no prescription. For more information, visit **signos.com**.

WEX Inc., FSA Store Inc., and Signos, Inc. are independent, non-affiliated entities. The Health-Commerce, Patiently, FSA Store and HSA Store names are pending or registered trademarks of FSA Store Inc. Please note that all specific claims, performance data, warranties, and representations regarding the Patiently™ and Signos GLP-1 offerings are made solely and independently by FSA Store Inc. and Signos, Inc. respectively.

Press Contact

Kelly Zalis
kelly.zalis@wexinc.com

Source: WEX